Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Viva Gold Reports Multiple High-Grade Gold Hits at the Tonopah Gold Project (click to learn more) Xcyte Digital Corp. Signs Agreement to Purchase Assets of Webinar.net (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Incyte Corp INCY

Healthcare Biotechnology
Incyte Corporation is a biopharmaceutical company, which is focused on the discovery, development, and commercialization of therapeutics. The Company also conducts clinical development and commercial operations from its European headquarters in Morges, Switzerland and its other offices across Europe, as well as its Japanese office in Tokyo and its Canadian headquarters in Montreal. It operates... see more

Recent & Breaking News (NDAQ:INCY)

Updated Phase 1 Data Reinforce the Clinical Profile of Epacadostat in Combination with Keytruda® (Pembrolizumab)

Business Wire September 28, 2016

NCCN Guidelines® Recommend Jakafi® (ruxolitinib) for the Treatment of Myelofibrosis

Business Wire September 27, 2016

Incyte Supports Those Affected by Rare Blood Cancers on MPN Awareness Day and Throughout Blood Cancer Awareness Month

Business Wire September 8, 2016

Janney Initiates Galapagos At Buy, Sees Fair Value Of Shares At $64

Benzinga.com  August 30, 2016

Incyte to Present at Upcoming Investor Conferences

Business Wire August 30, 2016

Forbes Magazine Names Incyte to its List of World’s Most Innovative Companies for Second Consecutive Year

Business Wire August 25, 2016

Incyte Reports 2016 Second-Quarter Financial Results and Updates Key Clinical Programs

Business Wire August 9, 2016

Updated Data for Epacadostat, Incyte’s Selective IDO1 Inhibitor, Accepted for Presentation at the ESMO Annual Congress 2016

Business Wire July 19, 2016

Incyte to Report Second Quarter Financial Results

Business Wire July 14, 2016

FDA Grants Breakthrough Therapy Designation for Incyte’s Ruxolitinib (Jakafi®) in Acute Graft-Versus-Host Disease (GVHD)

Business Wire June 23, 2016

Incyte Announces First Patient Treated in ECHO-301 Phase 3 Study

Business Wire June 22, 2016

New Phase 3 Data Show Jakafi® (ruxolitinib) is Superior to Best Available Therapy in Patients with Polycythemia Vera (PV)

Business Wire June 10, 2016

Patient-reported outcomes across phase 3 studies of baricitinib demonstrate statistically significant improvements in physical function and quality of life symptoms in patients with rheumatoid arthritis (RA)

Canada NewsWire June 9, 2016

Baricitinib significantly reduces joint damage progression in rheumatoid arthritis in patients who do not respond to conventional DMARDs

Canada NewsWire June 9, 2016

Five-year Results from Phase 3 Study of Jakafi® (ruxolitinib) Show Sustained Overall Survival Benefit in Patients with Myelofibrosis (MF)

Business Wire June 6, 2016

Incyte and Moffitt Cancer Center Establish Multi-Year Oncology Research Alliance

Business Wire June 1, 2016

Incyte Announces the Launch of the Incyte Charitable Giving Foundation

Business Wire May 31, 2016

Incyte Highlights Jakafi® (ruxolitinib) and Capmatinib Abstracts to be Presented at the 2016 ASCO and EHA Annual Meetings

Business Wire May 19, 2016

Incyte to Present at Upcoming Investor Conferences

Business Wire May 18, 2016

Incyte et ARIAD annoncent un accord dans le cadre duquel Incyte rachètera les opérations européennes d'ARIAD et vendra sous licence Iclusig® (ponatinib) en Europe

Business Wire May 10, 2016